CSF2 and familial pancreatic carcinoma: In a phase II adjuvant study, GVAX, which is composed of allogenic irradiated pancreatic cancer cells, can generate granulocyte-macrophage colony stimulating factor (GM-CSF), result in the expansion of CD8+ T-cells and help patients to achieve longer survival times (14–16).